Portfolio Category: Pharmaceuticals

Raziel Therapeutics is advancing the science of fat removal treatments by harnessing the body’s natural healing mechanism. Backed by leading investors, we build on science developed at the Hebrew University in Jerusalem. Raziel is currently running several clinical studies for diverse fat disorder indications as well as for aesthetics.

Pepticom designs novel peptide drug candidates, utilizing unique biocomputational AI software, to optimize the discovery process, accelerate time to market and reduce development risks and costs. Our mission is to advance 21st century medicine by improving access to novel peptide therapeutics. We harness the power of AI to design the best peptide drugs possible by expanding the exploration process to uncharted chemical space.

ODE Pharma has developed an innovative and user-friendly biological medication that can potentially treat lung ailments and breathing difficulties, prevents deterioration of lung functions in people suffering from COVID-19, and enables them to recover quickly from the disease. The same pathological changes that compromise lung functions upon the COVID-19 infection also occur in other pulmonary diseases (e.g., Influenza, Asthma and CF) and thus can potentially be cured by our solution. ODE Pharma was born out of the collaboration between the Hebrew University of Jerusalem, Professor Shmuel Ben-Sasson (inventor and lead scientist) and Pollen Innovation Ltd, an Israeli-based investment firm focused on accelerating disruptive innovations and trends that enhance quality of life and contribute to a better and healthier world.

Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by pioneering the development of next generation immune oncology (IO) therapies.

Lyotropic Delivery Systems (LDS) is based on the know-how and many years of research of Prof. Nissim Garti. Garti’s technology led to LDS’s establishment in 2013, and since then has extended its expertise in the field of delivery, developing new and more advanced technologies and strengthening the company’s IP.

Our unique technology is based chemically on polyethylene oxide and polypropylene oxide segments and differs markedly from common hydrogels. Its features allow Inteligels to redesign skin covers, physical barriers, and drug delivery in a painless and environmentally responsible way. It can be applied as nontoxic, solidifying products that begin as liquid gels, sprays, or sheets.

Many drugs can trigger serious side effects due to their chemical structure. At BioNanoSim we redesign these medicines using our proprietary nano-encapsulation technology. We make them significantly better than the original form with improved potency and less risk.

Revolutionizing diabetes treatment. Betalin is currently carrying pre-clinical studies and in discussions with both the Human Tissue Association (UK) and Food Drug Association (US) to begin clinical trials. Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.  

We at CardioVia provide the physicians with a minimal invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​The CardioVia device includes a delivery device that allows controlled and measured progress; CardioVia will Automatically identify and halt at the entrance of the pericardium using the bioimpedance sensor.